FI954964A0 - Användande av vWF-haltiga koncentrat som kombinationsterapi vid terapi med antitrombotika och fibrinolytika - Google Patents

Användande av vWF-haltiga koncentrat som kombinationsterapi vid terapi med antitrombotika och fibrinolytika

Info

Publication number
FI954964A0
FI954964A0 FI954964A FI954964A FI954964A0 FI 954964 A0 FI954964 A0 FI 954964A0 FI 954964 A FI954964 A FI 954964A FI 954964 A FI954964 A FI 954964A FI 954964 A0 FI954964 A0 FI 954964A0
Authority
FI
Finland
Prior art keywords
vwf
antithrombotic
combination therapy
containing concentrates
fibrinolytic drugs
Prior art date
Application number
FI954964A
Other languages
English (en)
Finnish (fi)
Other versions
FI954964A (sv
Inventor
Martin Reers
Gerhard Dickneite
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of FI954964A0 publication Critical patent/FI954964A0/sv
Publication of FI954964A publication Critical patent/FI954964A/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI954964A 1994-10-20 1995-10-18 Användande av vWF-haltiga koncentrat som kombinationsterapi vid terapi med antitrombotika och fibrinolytika FI954964A (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4437544A DE4437544A1 (de) 1994-10-20 1994-10-20 Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika

Publications (2)

Publication Number Publication Date
FI954964A0 true FI954964A0 (sv) 1995-10-18
FI954964A FI954964A (sv) 1996-04-21

Family

ID=6531287

Family Applications (1)

Application Number Title Priority Date Filing Date
FI954964A FI954964A (sv) 1994-10-20 1995-10-18 Användande av vWF-haltiga koncentrat som kombinationsterapi vid terapi med antitrombotika och fibrinolytika

Country Status (20)

Country Link
US (1) US5571784A (sv)
EP (1) EP0713881A3 (sv)
JP (1) JPH08208504A (sv)
KR (1) KR960013383A (sv)
CN (1) CN1128168A (sv)
AU (1) AU708670B2 (sv)
CA (1) CA2160975A1 (sv)
CZ (1) CZ287878B6 (sv)
DE (1) DE4437544A1 (sv)
FI (1) FI954964A (sv)
HR (1) HRP950525A2 (sv)
HU (1) HU219595B (sv)
IL (1) IL115652A (sv)
NO (1) NO954175L (sv)
NZ (1) NZ280274A (sv)
PL (1) PL183182B1 (sv)
SK (1) SK129695A3 (sv)
TW (1) TW398977B (sv)
UY (1) UY24063A1 (sv)
ZA (1) ZA958838B (sv)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5772629A (en) * 1995-10-23 1998-06-30 Localmed, Inc. Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
AT409335B (de) * 1998-11-10 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
JP2003284570A (ja) 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
US20130040888A1 (en) * 2010-02-16 2013-02-14 Novo Nordisk A/S Factor VIII Molecules With Reduced VWF Binding
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
TWI580423B (zh) * 2013-12-24 2017-05-01 財團法人工業技術研究院 緩解或治療痛風之醫藥組合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5200510A (en) * 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US4774323A (en) * 1987-06-29 1988-09-27 Rorer Pharmaceutical Corporation Purification of von Willebrand Factor solutions using gel permeation chromatography
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
GB8823480D0 (en) * 1988-10-06 1988-11-16 Ciba Geigy Ag Antidote
US5204323B1 (en) 1988-10-06 1995-07-18 Ciba Geigy Corp Hirudin antidotal compositions and methods
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
DE4115453A1 (de) * 1991-05-11 1992-11-12 Knoll Ag Neue wirkstoffkombination
US5366869A (en) * 1991-11-08 1994-11-22 Sheldon Goldstein Multiple coagulation test device and method
DE4203965A1 (de) * 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
JPH08512291A (ja) * 1993-04-23 1996-12-24 バイオ−テクノロジー・ジェネラル・コーポレーション 血栓溶解の増強方法
DE4430205A1 (de) * 1994-08-26 1996-02-29 Behringwerke Ag Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung

Also Published As

Publication number Publication date
NO954175L (no) 1996-04-22
CZ287878B6 (cs) 2001-03-14
DE4437544A1 (de) 1996-04-25
KR960013383A (ko) 1996-05-22
CN1128168A (zh) 1996-08-07
NZ280274A (en) 1997-01-29
US5571784A (en) 1996-11-05
IL115652A (en) 2000-08-31
HRP950525A2 (en) 1997-04-30
AU708670B2 (en) 1999-08-12
NO954175D0 (no) 1995-10-19
AU3430495A (en) 1996-05-02
EP0713881A2 (de) 1996-05-29
HUT73762A (en) 1996-09-30
SK129695A3 (en) 1996-10-02
FI954964A (sv) 1996-04-21
IL115652A0 (en) 1996-01-19
PL183182B1 (pl) 2002-06-28
CA2160975A1 (en) 1996-04-21
PL311031A1 (en) 1996-04-29
EP0713881A3 (de) 1996-08-21
ZA958838B (en) 1996-05-13
UY24063A1 (es) 1995-10-24
CZ271995A3 (en) 1996-05-15
HU219595B (hu) 2001-05-28
HU9503031D0 (en) 1995-12-28
JPH08208504A (ja) 1996-08-13
TW398977B (en) 2000-07-21

Similar Documents

Publication Publication Date Title
NO970468D0 (no) Jernholdige nanopartikler med dobbelt belegning og deres anvendelse i diagnostikk og terapi
NO992373L (no) Forlenget anestesi i ledd og kroppshulrom
IL113844A (en) N-(alpha-ETHYLBENZYL)-3-HYDROXY-2-PHENYLQUINOLINE-4-CARBOXAMIDE AND ITS USE IN THE PREPARATION OF MEDICAMENTS
NO942283L (no) Pyrofeoforbider og deres anvendelse i fotodynamisk terapi
EE04566B1 (et) Epotilooni derivaadid ja nende kasutamine meditsiinis
ZA949104B (en) Recombinant viruses and their use in gene therapy
FI944600A (sv) Imidazol-4-ylpiperidinderivat, framställning av dessa och användning av dessa inom terapin
HU9801634D0 (en) Genetically modified cells and their use in prevention or therapy of disease
FI954964A0 (sv) Användande av vWF-haltiga koncentrat som kombinationsterapi vid terapi med antitrombotika och fibrinolytika
IL111682A0 (en) Recombinant viruses and their use in gene therapy
BR8901727A (pt) Composicao organopolissiloxana estavel em ausencia de unidade e endurecivel em um elastomero
GB9419553D0 (en) Polypeptides and their use in the treatment of auto-immune disease
GB2275029B (en) Improvements in and relating to wheelchairs
PL320922A1 (en) Application of mhc-ii bonding and/or somulating molecules in prevention and/or treatment of diseases involving inflammatory processes
FI940186A0 (sv) 9H-imidazo/1,2-a/bensimidazol-3-acetamidderivat, deras framställning och deras användning inom terapi
FI973185A0 (sv) Användning av melatonin för behandling av patienter som lider av läkemedelsberoende
ZA932761B (en) Diamine derivatives and application thereof in therapeutic fields
ZA983740B (en) Novel amidine derivatives and their use in therapy
IL123156A0 (en) Benzenesulphonamide derivatives their preparation and their application in therapy
FI955537A0 (sv) Fibrinolytiska och koagulationshämmande proteiner
GB9401745D0 (en) Improvements in and relating to the administration of medicaments or therapeutic substances
PH23435A (en) Benzamide and application thereof in the therapeutic field
BR9709219A (pt) Utilização do brometo de pinaverium na prevenção dos fenômenos proliferativos das células do trata hepatodigestivo e das doenças que daí resultam
FI940185A (sv) Salter av 4-pyrimidinonderivat, deras framställning och användning inom terapi
IL109356A0 (en) N-substituted-2-azetidinones and their use in the preparation of n-unsubstituted-2-azetidinones